Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83 - 06/12/18
Doi : 10.1016/j.jaci.2018.07.029
Christian Zwicker, MSc a, Priya Sarate, MSc a, Mirjana Drinić, MSc a, Katharina Ambroz, BSc a, Elke Korb, MSc a, Ursula Smole, PhD b, Cordula Köhler, BSc b, Mark S. Wilson, PhD c, Hana Kozakova, PhD d, Peter Sebo, PhD e, Miloslav Kverka, MD, PhD e, Ursula Wiedermann, MD, MSc, PhD a, Irma Schabussova, PhD a 
a Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria
b Institute of Immunology, Medical University of Vienna, Vienna, Austria
c Immunology Discovery, Genentech, South San Francisco, Calif
d Laboratory of Gnotobiology, Institute of Microbiology, Czech Academy of Sciences, Nový Hrádek, Czech Republic
e Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
| Supported by Austrian Science Fund (FWF) grants SFB 4612 (to U.W. and I.S.), SFB 4609 (to U.S. and C.K.), and Doctoral Program MCCA DK W1248-B13 (to C.Z., P.S., U.W. and I.S.) and DK W1248 (to U.S. and C.K.), and OeAD grants CZ 15/2015 (to C.Z., P.S., M.D., H.K., and I.S.) and CZ 13/2016 (to C.Z., P.S., M.D., M.K., and I.S.). |
|
| Disclosure of potential conflict of interest: M. S. Wilson is an employee of Genentech and owns Genentech stock. P. Sebo is a founder and shareholder of Revabiotech SE, which develops a next generation of whole cell pertussis vaccines. U. Wiedermann is member of the SAB and supporting CSO of the biotech company Imugene, Australia, developing B cell cancer vaccines and is also member of the Austrian Advisory Board of Immunizations of the government of Health in Austria. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 6
P. 1987 - décembre 2018 Retour au numéro
Article précédent
- Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity
- Caroline B.K. Mathiesen, Michael C. Carlsson, Stephanie Brand, Svenning Rune Möller, Manja Idorn, Per thor Straten, Anders E. Pedersen, Sally Dabelsteen, Adnan Halim, Peter Adler Würtzen, Jens Brimnes, Henrik Ipsen, Bent L. Petersen, Hans H. Wandall
- Fel d 1 and Fel d 4 levels in cat fur, saliva, and urine
- Suzanne M. Kelly, Jacob Karsh, Jennifer Marcelo, Douglas Boeckh, Nate Stepner, Bryan Santone, Jimmy Yang, William H. Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?